Front > HEALTHCARE

HEALTHCARE

Dr. Yaron Daniely (left) and Dr. Ronny Gal  credit: Cadya Levy The exec who decides which drugs Novartis will develop

Dr. Ronny Gal, Novartis's Chief Strategy and Growth Officer: Our aim is that half our innovative products should come from outside the company.

Avi Spier, Novartis Executive Director Business Development and Licensing  credit: Cadya Levy The scout who learned to look for the quiet ones

Dr. Avi Spier, Executive Director Business Development and Licensing at Novartis, on how to find successful partnerships.

Dr. Tamar Alon   credit: Cadya Levy "We seek star researchers, pioneers in their fields"

Novartis’s Dr. Tamar Alon and Dr. Evan M. Beckman talk about the types of research that can drive the company's growth.

Eliran Elimelech, SNC VP of Ecosystem Development  credit: Cadya Levy Startup Nation Central data reveal the opportunities

Eliran Elimelech, Startup Nation Central VP of Ecosystem Development: Most of the companies are in AI and pharma.

Novartis Israel Country President Elad Maron  credit: Cadya Levy "We want to be a bridge between Israel and the world in biomed"

In Israel, Novartis focuses on marketing and clinical trials, but Country President Elad Maron says, "We know we can do much more. We want to make our mark beyond Israel in the biomedical industry."

Teva  credit: Cineberg/Shutterstock Teva schizophrenia drug Phase III results excite analysts

Evercore ISI analyst Umer Raffat believes that sales could amount to more than $1 billion annually.

Teva CEO Richard Francis credit: Elad Malka Teva hits five-year high after Q1 results

The Israeli pharmaceuticals company has reaffirmed its outlook for 2024 after higher revenue and a narrower loss in the first quarter of 2024.

Biotech credit: Gorodenkoff Shutterstock Israeli biotech co Nectin Therapeutics raises $10m

Nectin develops novel targeted immunotherapies that address resistance to approved immune oncology treatments.

Dollars credit: Colin Watts, Unsplashed Alcon to buy Israeli glaucoma treatment co Belkin Vision

The Swiss-American ophthalmology company will pay $60 million immediately and up to $335 million with milestone payments for the company, BioLight reports.

Dot Compliance founder Doron Sitbon AI that speeds up decision making in biomed

Dot Compliance provides AI-based solutions for quality control in life sciences, where time is a great deal of money.

Hospital  credit: Shutterstock Leumit and Meuhedet awarded new Beersheva hospital

Beersheva's second hospital will be operated by Sheba Medical Center, and is due to open by 2028.

Richard Francis  credit: PR Teva CEO Francis becomes highest paid TASE co exec

Richard Francis's compensation cost $25.7 million in 2023, although that includes incentives for him to join the company.

Vision  credit: Eyal Fischer RevitalVision announces success in two new trials

RevitalVision's products treat certain eye conditions by retraining the brain.

Gamida-Cell  credit: Eyal Izhar Two Elbit Medical exit dreams punctured in a week

InSightec and Gamida-Cell were two great hopes of Israel's biomed industry, but the one faces an uncertain future while Elbit Medical has relinquished the other in a debt settlement.

Gamida Cell  credit: EYal Izhar Gamida Cell to delist as Highbridge takes full ownership

The Israeli stem cell company will lay off 25% of its workforce and close its Jerusalem development center.

Teva CEO Richard Francis credit: Teva Spokesperson FDA rejects Mapi-Viatris long-acting version of Teva's Copaxone

Israeli company Mapi could receive milestone payments from Viatris worth tens of millions of dollars, and royalties from sales, if the product ever reaches the market.

Phage therapy co BiomX merges with APT, raises $50m

The Israeli company's share price jumped 150% on the news.

Healthee team credit: Healthee PR Employer healthcare costs co Healthee raises $32m

The Israeli company has developed a platform to enhance care outcomes and reduce overheads for both employers and employees.

Micha Breakstone  credit: Jonathan Bloom Stem cells meet AI

Together with Harvard and MIT scientists, Micha Breakstone founded Somite.ai, which combines stem cell and AI techniques to develop new therapies.

"Newsweek" lists Israeli hospital in world's best ten

The US magazine has named Sheba Medical Center in Tel Hashomer as the world's ninth best hospital.

start-ups FDA approves X-trodes monitoring patch

The product can measure brain and heart activity and many other physiological signs.

Teva CEO Richard Francis credit: Teva Spokesperson Teva CEO: It's a long way back to being 'share of the nation'

Richard Francis is confident that Teva's share price will continue to rise but says it will take many years to get back to its 2015 peak.

Biotech news credit: Tali Bogdanovsky, Shutterstock Kadimastem plans listing on Nasdaq through merger

The Israeli biotech stem cell company will delist from the TASE.

Brainsway on the rise credit: Tali Bogdanosky New business model transforms Brainsway's fortunes

The company, which has developed and marketings a helmet for deep transcranial magnetic stimulation, has seen its share price rise 230% in the past year.

Teva's R&D labs in Netanya  credit: Teva PR Teva enlarges workforce for first time since 2016

The Israeli pharmaceutical company had 36,472 employees at the end of 2023, up 3.8% from 2022, as it returned to growth.

Vincent Tchenguiz Photo: Christopher Ratcliffe Bladder cancer treatment co Vessi Medical raises $16.5m

Vessi's minimally invasive solution for NMIBC provides a new therapeutic alternative to transurethral resection of bladder tumor.

Naftali Bennett credit: Yediot Ahronot Yoav Dudkevitch Naftali Bennett joins board of Israeli biotech co

Former Israeli Prime Minister Naftali Bennett has joined the board of Remepy, which is pioneering hybrid drugs that include therapeutic applications that enhance the drug effect.

Researchers survey  credit: Gil Gibli Global academic community snubbbing Israeli researchers

A survey finds young Israeli researchers struggling to secure vital international collaboration, and that more wish to leave the country.

Teva  credit: Cineberg/Shutterstock Analysts bullish on Teva

Data from "The Wall Street Journal" show that just three months ago the analysts' consensus on Teva's share price was neutral, whereas today it is positive.

Dr. Ami Appelbaum  credit: Jonathan Bloom Israels former top scientist lashes out

After six years as chair of the Israel Innovation Authority, Dr. Ami Appelbaum champions its independence from political control, and describes his fears and hopes for Israel's tech sector.

Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018